SMARCA4 and lung carcinoma: In addition, BRG1 loss, together with its broad downstream epigenetic and gene expression changes, sensitizes lung cancer cells to various drugs, and these therapeutic vulnerabilities must be carefully exploited to improve the treatment of this leading cause of cancer-related death worldwide.